Milrinone and levosimendan during porcine myocardial ischemia - No effects on calcium overload and metabolism

Acta Anaesthesiologica Scandinavica

Volumn 57, Issue 6, 2013, Pages 719-728

  Axelsson, B ^a   Johansson, G ^c   Abrahamsson, P ^c   Gupta, A ^a,b   Tyden H ^a   Wouters, P ^d   Haney, M ^c  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM ION; GLUCOSE; GLYCEROL; LACTIC ACID; LEVOSIMENDAN; MILRINONE; PLACEBO; PYRUVIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CALCIUM METABOLISM; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; ENERGY CONSERVATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; IN VIVO STUDY; INOTROPISM; METABOLIC PARAMETERS; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCIUM; CALCIUM RADIOISOTOPES; CARDIOTONIC AGENTS; DRUG EVALUATION, PRECLINICAL; ENERGY METABOLISM; GLUCOSE; GLYCOLYSIS; HEART VENTRICLES; HEMODYNAMICS; HYDRAZONES; INFUSIONS, INTRAVENOUS; ION TRANSPORT; MICRODIALYSIS; MILRINONE; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; OXYGEN CONSUMPTION; PREMEDICATION; PYRIDAZINES; RANDOM ALLOCATION; SUS SCROFA; SWINE;

EID: 84878828910     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12095     Document Type: Article

References (32)

1. Waldenström AP, Hjalmarson AC, Thornell L,. A possible role of noradrenaline in the development of myocardial infarction: an experimental study in the isolated rat heart. Am Heart J 1978; 95: 43-51.
2. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J Jr, Braunwald E,. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971; 43: 67-82.
3. Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A,. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology 2008; 108: 979-987.
4. Herlitz J, Emanuelsson H, Swedberg K, Vedin A, Waldenström A, Waldenström J, Hjalmarson A,. Goteborg Metoprolol Trial: enzyme-estimated infarct size. Am J Cardiol 1984; 53: 15D-21D.
5. Herlitz J, Waldenström J, Hjalmarson A,. Infarct size limitation after early intervention with metoprolol in the MIAMI Trial. Cardiology 1988; 75: 117-122.
6. Hein M, Roehl AB, Baumert JH, Scherer K, Steendijk P, Rossaint R,. Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta Anaesthesiol Scand 2009; 53: 941-948.
7. Huang MH, Wu Y, Nguyen V, Rastogi S, McConnell BK, Wijaya C, Uretsky BF, Poh KK, Tan HC, Fujise K,. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther 2011; 25: 223-232.
8. Metzsch C, Liao Q, Steen S, Algotsson L,. Levosimendan cardioprotection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model. Acta Anaesthesiol Scand 2007; 51: 86-93.
9. Use T, Makita T, Ureshino H, Cho S, Yoshitomi O, Akiyama D, Oshibuchi M, Hara T, Sumikawa K,. Milrinone administered before ischemia or just after reperfusion, attenuates myocardial stunning in anesthetized swine. Cardiovasc Drugs Ther 2006; 20: 327-334.
10. Omerovic E, Ramunddal T, Albertsson P, Holmberg M, Hallgren P, Boren J, Grip L, Matejka G,. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction. Vasc Health Risk Manag 2010; 6: 657-663.
11. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
12. Bålfors E, Häggmark S, Ariola S Jr, Biber B, Pontén J, Reiz S,. In vitro analysis of thermal transport in coronary sinus thermodilution catheters. Clin Physiol 1983; 3: 469-476.
13. Abrahamsson P, Johansson G, Åberg AM, Haney M, Winsö O,. Optimised sample handling in association with use of the CMA 600 analyser. J Pharm Biomed Anal 2008; 48: 940-945.
14. Ronquist G, Frithz G,. Decreased 45calcium uptake in red cells of patients with essential hypertension. Acta Med Scand 1988; 224: 445-449.
15. Waldenström A, Ronquist G, Åberg A-M, Ahlström K, Hauck P, Abrahamsson P, Johansson G, Biber B, Haney MF,. Ischaemic preconditioning reduces myocardial calcium overload in coronary-occluded pig hearts shown by continuous in vivo assessment using microdialysis. Clin Physiol Funct Imaging 2012; 32: 133-138.
16. Hyldebrandt JA, Larsen SH, Schmidt MR, Hjortdal VE, Ravn HB,. Age-dependent effects of milrinone and levosimendan on ventricular function and haemodynamics in newborn and mature pigs. Cardiol Young 2011; 21: 518-527.
17. Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, Fryer RM,. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol 2008; 294: H238-248.
18. Grose R, Strain J, Greenberg M, LeJemtel TH,. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 1986; 7: 1107-1113.
19. Kabela E, Barcenas L, Farah A,. The effects of milrinone (Win 47203) on the coronary blood flow and oxygen consumption of the dog heart-lung preparation. Am Heart J 1986; 111: 702-709.
20. Monrad ES, Baim DS, Smith HS, Lanoue A, Brauwald E, Grossman W,. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 1985; 71: 972-979.
21. Kaheinen P, Pollesello P, Levijoki J, Haikala H,. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 2004; 43: 555-561.
22. Murphy E, Steenbergen C,. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008; 88: 581-609.
23. Waldenström A, Haney M, Biber B, Kavianipour M, Moritz T, Strandén P, Wikström G, Ronquist G,. Ischaemic preconditioning is related to decreasing levels of extracellular adenosine that may be metabolically useful in the at-risk myocardium: an experimental study in the pig. Acta Physiol (Oxf) 2010; 199: 1-9.
24. Metzsch C, Linner R, Steen S, Liao Q, Algotsson L,. Levosimendan cardioprotection in acutely beta-1 adrenergic receptor blocked open chest pigs. Acta Anaesthesiol Scand 2010; 54: 103-110.
25. Ahlstrom K, Biber B, Aberg A, Waldenstrom A, Ronquist G, Abrahamsson P, Stranden P, Johansson G, Haney MF,. Metabolic responses in ischemic myocardium after inhalation of carbon monoxide. Acta Anaesthesiol Scand 2009; 53: 1036-1042.
26. Meyer K, Schipke JD, Klocke RC, Gams E, Korbmacher B,. Inotropic, vasodilating and preconditioning actions of levosimendan in the heart. Thorac Cardiovasc Surg 2008; 56: 379-385.
27. Busk M, Maeng M, Kristensen J, Berg JS, Mortensen UM, Nielsen TT, Nielsen-Kudsk JE,. Effects of levosimendan on myocardial infarct size and hemodynamics in a closed-chest porcine ischemia-reperfusion model. Cardiovasc Drugs Ther 2006; 20: 335-342.
28. Caimmi PP, Molinari C, Uberti F, Micalizzi E, Valente G, Mary DA, Vacca G, Grossini E,. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg 2011; 39: e59-67.
29. Honisch A, Theuring N, Ebner B, Wagner C, Strasser RH, Weinbrenner C,. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol 2010; 105: 155-167.
30. Kersten JR, Montgomery MW, Pagel PS, Warltier DC,. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90: 5-11.
31. Uberti F, Caimmi PP, Molinari C, Mary D, Vacca G, Grossini E,. Levosimendan modulates programmed forms of cell death through K(ATP) channels and nitric oxide. J Cardiovasc Pharmacol 2011; 57: 246-258.
32. Näslund U, Häggmark S, Johansson G, Marklund SL, Reiz S,. Limitation of myocardial infarct size by superoxide dismutase as an adjunct to reperfusion after different durations of coronary occlusion in the pig. Circ Res 1990; 66: 1294-1301.